Fady I Malik - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Fady I Malik

Showing results (41-50 of 120) with videos related to

Pageof 12

Sort By:

Journal of Medicinal Chemistry|March 7, 2024

Cardiac Troponin Activator <b>CK-963</b> Increases Cardiac Contractility in RatsScott E Collibee, Antonio Romero, Alexander R Muci, et al.

The Journal of General Physiology|February 20, 2024

Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathyRicardo A Galli, Tamara C Borsboom, Charlotte Gineste, et al.

JACC. Heart Failure|December 3, 2014

Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.

European Journal of Heart Failure|July 18, 2024

Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.

Scientific Reports|January 2, 2023

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathyAshley N Sharpe, Maureen S Oldach, Victor N Rivas, et al.

Circulation. Heart Failure|November 8, 2021

Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on EnergeticsHuamei He, Tomas Baka, James Balschi, et al.

European Journal of Heart Failure|October 9, 2020

Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fractionAlia S Alhakak, Morten Sengeløv, Peter G Jørgensen, et al.

European Journal of Heart Failure|March 2, 2026

Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.

American Journal of Physiology. Lung Cellular and Molecular Physiology|May 19, 2016

Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertensionEmmy Manders, Peter I Bonta, Jaap J Kloek, et al.

Lancet (London, England)|August 23, 2011

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyJohn R Teerlink, Cyril P Clarke, Khalil G Saikali, et al.

Pageof 12

Search research articles

Showing results (41-50 of 120) with videos related to

Sort By:

Pageof 12

Journal of Medicinal Chemistry|March 7, 2024

Cardiac Troponin Activator <b>CK-963</b> Increases Cardiac Contractility in RatsScott E Collibee, Antonio Romero, Alexander R Muci, et al.

The Journal of General Physiology|February 20, 2024

Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathyRicardo A Galli, Tamara C Borsboom, Charlotte Gineste, et al.

JACC. Heart Failure|December 3, 2014

Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.

European Journal of Heart Failure|July 18, 2024

Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.

Scientific Reports|January 2, 2023

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathyAshley N Sharpe, Maureen S Oldach, Victor N Rivas, et al.

Circulation. Heart Failure|November 8, 2021

Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on EnergeticsHuamei He, Tomas Baka, James Balschi, et al.

European Journal of Heart Failure|October 9, 2020

Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fractionAlia S Alhakak, Morten Sengeløv, Peter G Jørgensen, et al.

European Journal of Heart Failure|March 2, 2026

American Journal of Physiology. Lung Cellular and Molecular Physiology|May 19, 2016

Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertensionEmmy Manders, Peter I Bonta, Jaap J Kloek, et al.

Lancet (London, England)|August 23, 2011

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyJohn R Teerlink, Cyril P Clarke, Khalil G Saikali, et al.

Pageof 12